Deepening the 12th Five-year Medical Reform: Imported Drugs or Centralized Procurement

"Intensify reforms in the field of pharmaceutical production and circulation, strictly enforce drug access, ensure the safety and effectiveness of drugs, explore non-essential drugs, medical consumables, and large-scale equipment in the scope of centralized bidding, and import drugs to implement centralized procurement to reduce costs." August 17, Ministry of Health Minister Chen Hao expressed at the 2012 China Health Forum.

Chen Xi pointed out that in order to deepen the phased goals of the 12th Five-Year Plan, an important point is to reform and improve the pharmaceutical supply security system. That is, to deepen reforms in the field of pharmaceutical production and circulation, strict drug access, and ensure the safety and effectiveness of drugs. Exploration of non-essential drugs, medical consumables, and large-scale equipment are all included in the scope of centralized bidding. Imported drugs are subject to centralized procurement to reduce costs. Improve the pharmaceutical industry development policies and industry development plans, improve the independent innovation capability of pharmaceutical companies, and promote the optimization and upgrading of the pharmaceutical industry.

"The reform of public hospitals is the hard bone in medical reform." Chen Yu further pointed out that we must continue to improve the top-level design of public hospitals and comprehensively advance the reform of public hospitals on the basis of pilots. Moreover, county-level public hospitals are the focus of the reform of the Ministry of Health for the next four years. The key points of the reform are to eliminate the mechanism of drug supplementation, establish a scientific and reasonable compensation mechanism, give full play to the enthusiasm of medical staff, grasp talents, establish a standardized training system, and train large-scale general practitioners in multiple channels and situations to reform the future medical care. The revolutionary measures of the health service pattern; multi-channels, strive to achieve 20% of the number of beds in social institutions in 2015.

In order to deepen the phased goals that have been achieved in the 12th Five-Year Plan of Medical Reform, Chen Xi proposed the overall goals of the recent medical reform work, namely, improve health insurance, standardize medicine, innovate medical care, and realize three-wheel drive of medical insurance, medical care, and medicine. “This is the basic strategy for deepening medical reform.” "" Chen Yu said at the forum.

Chen Hao disclosed to the media at the forum that in 2012, the Ministry of Health will publish the 2012 edition of the National Essential Drugs Catalogue, focusing on solving orphan drug use, children's drug preparations, and shortage of drug protection systems. With the improvement of the level of protection, it will continue to increase the proportion of basic drug reimbursement. . We will improve the national drug-oriented national drug policy, further clarify the attributes and safeguards of public goods for essential drugs, improve basic drug pricing, reimbursement, and other policies and measures, and link the reform of public hospital compensation mechanisms with the reform of medical insurance payments.

Chen Hao said that the reform of the compensation mechanism is important because the reform of the compensation mechanism is a key breakthrough in the reform of public hospitals. While implementing the government subsidy policy, medical insurance compensation should be fully utilized. An effective approach is to steadily advance reform reforms, reduce the reform of drug inspections, eliminate the mezzanine levels of drugs, and increase the technical service standards.

In the long run, the reform of the payment system should be promoted, and the profitability of project-based fees and pharmaceutical-based medical and pharmaceutical institutions should be turned into costs. In this way, the incentive to create income and control the cost of self-conscious, greatly reduce the waste of medicines, help the health insurance fund to control risks, promote sustainable development, help to establish a clinical path, and help motivate doctors to mobilize the enthusiasm of honest work.

Although the 12th five-year medical reform has achieved phased results, Chen Yu believes that as the reform advances in depth, the deeper contradictions between interest patterns, profound adjustments, institutional mechanisms, and structural issues are highlighted.

He pointed out that the advancement of the 12th five-year medical reform work faces two problems. The first level: Medicare, medical care, and medicine are managed by different departments. The internal coordination of the three systems is not sufficient. For example, there are still several systems for medical insurance management. The basic medicine system in medicine still requires extension of major hospitals, deep-level reform of public hospitals, and localization. Management has not yet been implemented.

The second level refers to the inadequacy of coordination between medical insurance, medicine, and the medical system. Chen Yun said frankly that the main reason for these problems is that China's medical reform is still in the stage of establishing a basic system. Each system and system has its own historical context. There is so-called path dependence and coordination is not difficult.

Chen Hao analyzed that from a worldwide perspective, many countries and regions that have established relatively mature countries have experienced such a stage in their history. Taking the medical insurance system as an example, from covering professional people to the universal coverage of various groups, many countries have spent decades. Therefore, it is difficult for China to skip this deep water stage.

API Medical

HOT SALE API product

Tryptamine,

N-isopropylbenzylamine,
ErdosteineFinasteride
Dutasteride
Amino-3-phenylbutyrate
Baclofen
Abiraterone
Tazobactam Diphenylmethyl Ester
L-Carnitine
Racecodotril
Ivermectin

Tauroursodeoxycholic Acid (TUDCA

package

Package2

Factory


Company Profile
Xi'an Jmlai Bio-Tech Co.,Ltd is Research, Production, Process and Sales. company mainly engaged in export of products including,without limitation, pharmaceutical raw materials both for vet and human, also Vitamins, Amino Acids, minerals, peptides,plantextract, feed and food additives. and provide natural and well-qualified raw materials to the companies being engaged in pharmaceutical,health product, nutritional product, cosmetic raw material,Sarms Products , Steroids Products Peptides Products, APIProducts, Plant Extract and HGH, HCG. with very strong strength in R&D, production, sale and other aspects in the national plant extract industry.
Jmlai has a professional R&D , production team, sales team and after-sales service .Our company's business is based on Honest,Trustworthy, Constantly to Go Beyond and AchieveMutual Win. Sincerely hope to strengthen exchanges and cooperation with friends from both home and abroad.


description


Api Medical,Amino-3-Phenylbutyrate,Tauroursodeoxycholic Acid (Tudca),Api Crl-40 Powder

Xi'an Jmlai Bio-Tech Co., Ltd. , https://www.jmlaisarms.com